

Susan M Domchek

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5226647/susan-m-domchek-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

315
papers

23,541
citations

74
h-index

147
g-index

346
ext. papers

28,826
ext. citations

8.5
avg, IF

6.44
L-index

#	Paper	IF	Citations
315	Abstract OT2-18-01: Harnessing olaparib, palbociclib, and endocrine therapy (HOPE): Phase I/II trial of olaparib, palbociclib and fulvestrant in patients with BRCA1/2-associated, hormone receptor-positive, HER2-negative metastatic breast cancer. <i>Cancer Research</i> , 2022 , 82, OT2-18-01-OT2-18-01	10.1	0
314	Abstract P2-09-01: Population-based risk estimates of clinical subtypes of breast cancer among carriers of germline pathogenic variants in cancer predisposition genes. <i>Cancer Research</i> , 2022 , 82, P2-09-01-P2-09-01	10.1	0
313	Abstract P2-11-21: Integration of an ancestrally unbiased polygenic risk score with the Tyrer-Cuzick breast cancer risk model. <i>Cancer Research</i> , 2022 , 82, P2-11-21-P2-11-21	10.1	0
312	Mutations and Cardiovascular Function in Breast Cancer Survivors.. <i>Frontiers in Cardiovascular Medicine</i> , 2022 , 9, 833171	5.4	0
311	Loss and Promoter Hypermethylation Negatively Predict for Immunogenicity in BRCA-Deficient Ovarian Cancer.. <i>JCO Precision Oncology</i> , 2022 , 6, e2100159	3.6	0
310	Risks of breast and ovarian cancer for women harboring pathogenic missense variants in BRCA1 and BRCA2 compared with those harboring protein truncating variants.. <i>Genetics in Medicine</i> , 2021 ,	8.1	2
309	Targeted BRCA1/2 population screening among Ashkenazi Jewish individuals using a web-enabled medical model: An observational cohort study.. <i>Genetics in Medicine</i> , 2021 ,	8.1	1
308	Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2021 , 163, 246-253	4.9	8
307	Germline Pathogenic Variants in Cancer Predisposition Genes Among Women With Invasive Lobular Carcinoma of the Breast. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3918-3926	2.2	6
306	What happens after menopause? (WHAM): A prospective controlled study of depression and anxiety up to 12 months after premenopausal risk-reducing bilateral salpingo-oophorectomy. <i>Gynecologic Oncology</i> , 2021 , 161, 527-534	4.9	3
305	Challenges and Opportunities in Engaging Primary Care Providers in BRCA Testing: Results from the BFOR Study. <i>Journal of General Internal Medicine</i> , 2021 , 1	4	2
304	Adjuvant Olaparib for Patients with - or -Mutated Breast Cancer. <i>New England Journal of Medicine</i> , 2021 , 384, 2394-2405	59.2	145
303	Comprehensive Breast Cancer Risk Assessment for and Pathogenic Variant Carriers Incorporating a Polygenic Risk Score and the Tyrer-Cuzick Model. <i>JCO Precision Oncology</i> , 2021 , 5,	3.6	2
302	The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant. <i>Genetics in Medicine</i> , 2021 , 23, 1726-1737	8.1	2
301	Randomized study of remote telehealth genetic services versus usual care in oncology practices without genetic counselors. <i>Cancer Medicine</i> , 2021 , 10, 4532-4541	4.8	4
300	What happens after menopause? (WHAM): A prospective controlled study of vasomotor symptoms and menopause-related quality of life 12 months after premenopausal risk-reducing salpingo-oophorectomy. <i>Gynecologic Oncology</i> , 2021 , 163, 148-154	4.9	1
299	Risk of Late-Onset Breast Cancer in Genetically Predisposed Women. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3430-3440	2.2	3

298	What Happens After Menopause? (WHAM): A prospective controlled study of cardiovascular and metabolic risk 12 months after premenopausal risk-reducing bilateral salpingo-oophorectomy. <i>Gynecologic Oncology</i> , 2021 , 162, 88-96	4.9	2
297	Real-world integration of genomic data into the electronic health record: the PennChart Genomics Initiative. <i>Genetics in Medicine</i> , 2021 , 23, 603-605	8.1	5
296	Clinical Characteristics of Patients With Pancreatic Cancer and Pathogenic Alterations. <i>JNCI Cancer Spectrum</i> , 2021 , 5, pkaa121	4.6	5
295	A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. <i>Nature Communications</i> , 2021 , 12, 1078	17.4	4
294	A Population-Based Study of Genes Previously Implicated in Breast Cancer. <i>New England Journal of Medicine</i> , 2021 , 384, 440-451	59.2	115
293	A prospective controlled study of sexual function and sexually related personal distress up to 12 months after premenopausal risk-reducing bilateral salpingo-oophorectomy. <i>Menopause</i> , 2021 , 28, 748-755	7.5	1
292	Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores. <i>Journal of the National Cancer Institute</i> , 2021 ,	9.7	3
291	Comparison of the Prevalence of Pathogenic Variants in Cancer Susceptibility Genes in Black Women and Non-Hispanic White Women With Breast Cancer in the United States. <i>JAMA Oncology</i> , 2021 , 7, 1045-1050	13.4	7
290	Uptake and acceptability of a mainstreaming model of hereditary cancer multigene panel testing among patients with ovarian, pancreatic, and prostate cancer. <i>Genetics in Medicine</i> , 2021 , 23, 2105-2113	8.1	2
289	Relationship of established risk factors with breast cancer subtypes. <i>Cancer Medicine</i> , 2021 , 10, 6456-6467	7.8	6
288	EUS-based Pancreatic Cancer Surveillance in Carriers Without a Family History of Pancreatic Cancer. <i>Cancer Prevention Research</i> , 2021 , 14, 1033-1040	3.2	0
287	Risk of Breast Cancer Among Carriers of Pathogenic Variants in Breast Cancer Predisposition Genes Varies by Polygenic Risk Score. <i>Journal of Clinical Oncology</i> , 2021 , 39, 2564-2573	2.2	12
286	Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in , , or . <i>Journal of Clinical Oncology</i> , 2021 , 39, 2497-2505	2.2	34
285	Risk factors for breast cancer subtypes among Black women undergoing screening mammography. <i>Breast Cancer Research and Treatment</i> , 2021 , 189, 827-835	4.4	2
284	What happens after menopause? (WHAM): A prospective controlled study of sleep quality up to 12 months after premenopausal risk-reducing salpingo-oophorectomy. <i>Gynecologic Oncology</i> , 2021 , 162, 447-453	4.9	0
283	Integrating Clinical and Polygenic Factors to Predict Breast Cancer Risk in Women Undergoing Genetic Testing. <i>JCO Precision Oncology</i> , 2021 , 5,	3.6	8
282	Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021 , 19, 77-102	7.3	131
281	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. <i>Nature Genetics</i> , 2020 , 52, 572-581	36.3	76

280	Contribution of Germline Predisposition Gene Mutations to Breast Cancer Risk in African American Women. <i>Journal of the National Cancer Institute</i> , 2020 , 112, 1213-1221	9.7	25
279	Longitudinal follow-up after telephone disclosure in the randomized COGENT study. <i>Genetics in Medicine</i> , 2020 , 22, 1401-1406	8.1	1
278	Integrating Genetic and Genomic Testing Into Oncology Practice. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020 , 40, e259-e263	7.1	3
277	Development and Validation of a Clinical Polygenic Risk Score to Predict Breast Cancer Risk. <i>JCO Precision Oncology</i> , 2020 , 4,	3.6	16
276	Evaluation of Germline Genetic Testing Criteria in a Hospital-Based Series of Women With Breast Cancer. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1409-1418	2.2	28
275	Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). <i>JAMA Oncology</i> , 2020 , 6, 1218-1230	13.4	25
274	Longitudinal outcomes with cancer multigene panel testing in previously tested BRCA1/2 negative patients. <i>Clinical Genetics</i> , 2020 , 97, 601-609	4	3
273	Loss-of-function variants in CTNNA1 detected on multigene panel testing in individuals with gastric or breast cancer. <i>Genetics in Medicine</i> , 2020 , 22, 840-846	8.1	15
272	Splicing profile by capture RNA-seq identifies pathogenic germline variants in tumor suppressor genes. <i>Npj Precision Oncology</i> , 2020 , 4, 4	9.8	16
271	Transcriptome-wide association study of breast cancer risk by estrogen-receptor status. <i>Genetic Epidemiology</i> , 2020 , 44, 442-468	2.6	9
270	Changes in Cardiovascular Biomarkers With Breast Cancer Therapy and Associations With Cardiac Dysfunction. <i>Journal of the American Heart Association</i> , 2020 , 9, e014708	6	44
269	Frequency of radiation-induced malignancies post-adjuvant radiotherapy for breast cancer in patients with Li-Fraumeni syndrome. <i>Breast Cancer Research and Treatment</i> , 2020 , 181, 181-188	4.4	14
268	Association of premenopausal risk-reducing salpingo-oophorectomy with breast cancer risk in BRCA1/2 mutation carriers: Maximising bias-reduction. <i>European Journal of Cancer</i> , 2020 , 132, 53-60	7.5	10
267	Association of Genomic Domains in and with Prostate Cancer Risk and Aggressiveness. <i>Cancer Research</i> , 2020 , 80, 624-638	10.1	22
266	NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020 , 18, 380-391	7.3	171
265	Comprehensive breast cancer (BC) risk assessment for CHEK2 carriers incorporating a polygenic risk score (PRS) and the Tyrer-Cuzick (TC) model.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1504-1504	2.2	
264	Current Insights: Evolving Principles and Controversies of Cancer Risk Assessment and Management of Hereditary Cancers. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020 , 18, 964-967	7.3	
263	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. <i>Nature Genetics</i> , 2020 , 52, 56-73	36.3	56

262	Cancer Risks Associated With Germline Pathogenic Variants: An International Study of 524 Families. <i>Journal of Clinical Oncology</i> , 2020 , 38, 674-685	2.2	133
261	CDH1 on Multigene Panel Testing: Look Before You Leap. <i>Journal of the National Cancer Institute</i> , 2020 , 112, 330-334	9.7	17
260	Germline genetic testing for breast cancer: which patients? What genes?. <i>Genetics in Medicine</i> , 2020 , 22, 698-700	8.1	1
259	Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation. <i>British Journal of Cancer</i> , 2020 , 122, 333-339	8.7	60
258	Reply to Patel and McLeod. <i>Journal of Clinical Oncology</i> , 2020 , 38, 284	2.2	
257	Endoscopic Ultrasound Has Limited Utility in Diagnosis of Gastric Cancer in Carriers of CDH1 Mutations. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 505-508.e1	6.9	12
256	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. <i>Genetics in Medicine</i> , 2020 , 22, 1653-1666	8.1	34
255	A Rare Mutation Predominant in Ashkenazi Jews Confers Risk of Multiple Cancers. <i>Cancer Research</i> , 2020 , 80, 3732-3744	10.1	7
254	Executive function after risk-reducing salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: does current mood and early life adversity matter?. <i>Menopause</i> , 2020 , 27, 746-755	2.5	4
253	The contemporary landscape of genetic testing and breast cancer: Emerging issues. <i>Breast Journal</i> , 2020 , 26, 1549-1555	1.2	4
252	Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study. <i>Lancet Oncology</i> , 2020 , 21, 1155-1164	21.7	98
251	Association of a Polygenic Risk Score With Breast Cancer Among Women Carriers of High- and Moderate-Risk Breast Cancer Genes. <i>JAMA Network Open</i> , 2020 , 3, e208501	10.4	38
250	TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes. <i>Journal of Clinical Oncology</i> , 2020 , 38, 4274-4282	2.2	92
249	Association of germline variation with the survival of women with pathogenic variants and breast cancer. <i>Npj Breast Cancer</i> , 2020 , 6, 44	7.8	3
248	Mutation Rates in Cancer Susceptibility Genes in Patients With Breast Cancer With Multiple Primary Cancers. <i>JCO Precision Oncology</i> , 2020 , 4,	3.6	2
247	Upper Gastrointestinal Cancer Risk and Surveillance Outcomes in Li-Fraumeni Syndrome. <i>American Journal of Gastroenterology</i> , 2020 , 115, 2095-2097	0.7	3
246	Comprehensive Assessment of Changes in Left Ventricular Diastolic Function With Contemporary Breast Cancer Therapy. <i>JACC: Cardiovascular Imaging</i> , 2020 , 13, 198-210	8.4	28
245	Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers. <i>European Urology</i> , 2019 , 76, 831-842	10.2	78

244	Broad Application of Multigene Panel Testing for Breast Cancer Susceptibility-Pandora [®] Box Is Opening Wider. <i>JAMA Oncology</i> , 2019 ,	13.4	13
243	RE: BRCA1 and BRCA2 Gene Mutations and Colorectal Cancer Risk: Systematic Review and Meta-analysis. <i>Journal of the National Cancer Institute</i> , 2019 , 111, 522-523	9.7	5
242	Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification. <i>Human Mutation</i> , 2019 , 40, 1557-1578	4.7	52
241	Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. <i>British Journal of Cancer</i> , 2019 , 121, 180-192	8.7	13
240	How Should Patients and Providers Interpret the US Food and Drug Administration [®] Regulatory Language for Direct-to-Consumer Genetic Tests?. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2514-2517	2.2	8
239	BRCA1 and BRCA2 pathogenic sequence variants in women of African origin or ancestry. <i>Human Mutation</i> , 2019 , 40, 1781-1796	4.7	16
238	Towards controlled terminology for reporting germline cancer susceptibility variants: an ENIGMA report. <i>Journal of Medical Genetics</i> , 2019 , 56, 347-357	5.8	19
237	Detailed phenotyping reveals distinct trajectories of cardiovascular function and symptoms with exposure to modern breast cancer therapy. <i>Cancer</i> , 2019 , 125, 2762-2771	6.4	7
236	Genomic Signatures Predict the Immunogenicity of BRCA-Deficient Breast Cancer. <i>Clinical Cancer Research</i> , 2019 , 25, 4363-4374	12.9	38
235	Research participants' experiences with return of genetic research results and preferences for web-based alternatives. <i>Molecular Genetics & Genomic Medicine</i> , 2019 , 7, e898	2.3	11
234	The p.Arg658* truncating variant is associated with risk of triple-negative breast cancer. <i>Npj Breast Cancer</i> , 2019 , 5, 38	7.8	12
233	Ten-fold increase in genetic testing in pancreatic and metastatic prostate cancer with implementation of point of care (POC) testing.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1506-1506	2.2	5
232	A randomized phase II trial of niraparib plus either nivolumab or ipilimumab in patients with advanced pancreatic cancer whose cancer has not progressed on platinum-based therapy.. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS4161-TPS4161	2.2	10
231	An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in patients with relapsed gastric cancer.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 140-140	2.2	25
230	EMR documentation of genetics evaluations in patients with ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e13156-e13156	2.2	
229	Genetic predisposition to breast cancer among African American women.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 104-104	2.2	
228	Risk factors for sexual dysfunction in BRCA mutation carriers after risk-reducing salpingo-oophorectomy. <i>Menopause</i> , 2019 , 26, 132-139	2.5	13
227	Identification and Confirmation of Potentially Actionable Germline Mutations in Tumor-Only Genomic Sequencing. <i>JCO Precision Oncology</i> , 2019 , 3,	3.6	9

226	Preferences for in-person disclosure: Patients declining telephone disclosure characteristics and outcomes in the multicenter Communication Of GENetic Test Results by Telephone study. <i>Clinical Genetics</i> , 2019 , 95, 293-301	4	8
225	Earlier Colorectal Cancer Screening May Be Necessary In Patients With Li-Fraumeni Syndrome. <i>Gastroenterology</i> , 2019 , 156, 273-274	13.3	14
224	Combination Paclitaxel and Palbociclib: Results of a Phase I Trial in Advanced Breast Cancer. <i>Clinical Cancer Research</i> , 2019 , 25, 2072-2079	12.9	24
223	Cardiovascular Function Phenotypes in Response to Cardiotoxic Breast Cancer Therapy. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 248-249	15.1	6
222	Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study. <i>Journal of the National Cancer Institute</i> , 2019 , 111, 350-364	9.7	22
221	Risk-Reducing Mastectomy in BRCA1 and BRCA2 Mutation Carriers: A Complex Discussion. <i>JAMA - Journal of the American Medical Association</i> , 2019 , 321, 27	27.4	15
220	Preventative Health and Risk Behaviors Among Adolescent Girls With and Without Family Histories of Breast Cancer. <i>Journal of Adolescent Health</i> , 2019 , 64, 116-123	5.8	1
219	Randomized Noninferiority Trial of Telephone vs In-Person Disclosure of Germline Cancer Genetic Test Results. <i>Journal of the National Cancer Institute</i> , 2018 , 110, 985-993	9.7	25
218	A counseling framework for moderate-penetrance colorectal cancer susceptibility genes. <i>Genetics in Medicine</i> , 2018 , 20, 1324-1327	8.1	20
217	Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. <i>Human Mutation</i> , 2018 , 39, 593-620	4.7	138
216	Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition. <i>British Journal of Cancer</i> , 2018 , 118, 266-276	8.7	9
215	A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. <i>Cancer Research</i> , 2018 , 78, 5419-5430	10.1	32
214	Ethical Implications of Direct-to-Consumer Hereditary Cancer Tests. <i>JAMA Oncology</i> , 2018 , 4, 1327-1328	13.4	10
213	Uptake of BRCA 1/2 and oncoTYPE DX testing by medical and surgical oncologists. <i>Breast Cancer Research and Treatment</i> , 2018 , 171, 173-180	4.4	4
212	A single arm phase II study of rucaparib maintenance in patients with advanced pancreatic adenocarcinoma and a known deleterious BRCA1, BRCA2 or PALB2 mutation who have achieved stability on platinum therapy.. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS531-TPS531	2.2	3
211	Retrospective Survival Analysis of Patients With Advanced Pancreatic Ductal Adenocarcinoma and Germline or Mutations.. <i>JCO Precision Oncology</i> , 2018 , 2, 1-9	3.6	11
210	Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy. <i>Journal of Clinical Oncology</i> , 2018 , 36, 3134-3143	2.2	29
209	Rapid detection of recurrent mutations in Chinese breast and ovarian cancer patients with multiplex SNaPshot genotyping panels. <i>Oncotarget</i> , 2018 , 9, 7832-7843	3.3	6

208	Returning Individual Genetic Research Results to Research Participants: Uptake and Outcomes Among Patients With Breast Cancer. <i>JCO Precision Oncology</i> , 2018 , 2,	3.6	8
207	BRCA Challenge: BRCA Exchange as a global resource for variants in BRCA1 and BRCA2. <i>PLoS Genetics</i> , 2018 , 14, e1007752	6	90
206	Pervasive genetic testing. <i>Lancet, The</i> , 2018 , 391, 2089-2091	40	3
205	The evolution of poly(ADP-ribose) polymerase inhibitors in the treatment of breast cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2018 , 16, 330-332	0.6	1
204	Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk - Combined Results from Two Screening Trials. <i>Clinical Cancer Research</i> , 2017 , 23, 3628-3637	12.9	68
203	Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. <i>New England Journal of Medicine</i> , 2017 , 377, 523-533	59.2	1405
202	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. <i>Nature Genetics</i> , 2017 , 49, 680-691	36.3	190
201	A Phase I-II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline -Mutated Ovarian Carcinoma or Other Solid Tumors. <i>Clinical Cancer Research</i> , 2017 , 23, 4095-4106	12.9	164
200	Olaparib for Metastatic Germline BRCA-Mutated Breast Cancer. <i>New England Journal of Medicine</i> , 2017 , 377, 1792-3	59.2	39
199	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. <i>Nature Genetics</i> , 2017 , 49, 1767-1778	36.3	186
198	Reply to R.L. Nussbaum et al and J.S. Dolinsky et al. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1262-1263	2.2	1
197	Identifying Health Information Technology Needs of Oncologists to Facilitate the Adoption of Genomic Medicine: Recommendations From the 2016 American Society of Clinical Oncology Omics and Precision Oncology Workshop. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3153-3159	2.2	19
196	Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2240-2250	2.2	101
195	Reversion Mutations with Clinical Use of PARP Inhibitors: Many Genes, Many Versions. <i>Cancer Discovery</i> , 2017 , 7, 937-939	24.4	16
194	BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers. <i>Nature Communications</i> , 2017 , 8, 319	17.4	139
193	Arginine-Nitric Oxide Metabolites and Cardiac Dysfunction in Patients With Breast Cancer. <i>Journal of the American College of Cardiology</i> , 2017 , 70, 152-162	15.1	59
192	A functionally significant SNP in TP53 and breast cancer risk in African-American women. <i>Npj Breast Cancer</i> , 2017 , 3, 5	7.8	29
191	Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. <i>Breast Cancer Research and Treatment</i> , 2017 , 161, 117-134	4.4	15

190	Reproductive Decision-Making in Women with BRCA1/2 Mutations. <i>Journal of Genetic Counseling</i> , 2017 , 26, 594-603	2.5	46
189	A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale. <i>Future Oncology</i> , 2017 , 13, 307-320	3.6	30
188	Physical and psychological health in rare cancer survivors. <i>Journal of Cancer Survivorship</i> , 2017 , 11, 158-165	1.5	11
187	Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers. <i>Journal of the National Cancer Institute</i> , 2017 , 109,	9.7	153
186	Extended follow-up in the COGENT study: A randomized study of in-person versus telephone disclosure of cancer genetic test results.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1504-1504	2.2	
185	Knowledge outcomes in a randomized trial of telephone vs. in-person disclosure of genetic testing: The COGENT study.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1534-1534	2.2	
184	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. <i>Gynecologic Oncology</i> , 2016 , 141, 386-401	4.9	15
183	Psychosocial Adjustment and Perceived Risk Among Adolescent Girls From Families With BRCA1/2 or Breast Cancer History. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3409-16	2.2	13
182	Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women. <i>Breast Cancer Research</i> , 2016 , 18, 112	8.3	25
181	Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. <i>Nature Communications</i> , 2016 , 7, 11375	17.4	64
180	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. <i>Nature Communications</i> , 2016 , 7, 12675	17.4	53
179	Use of systemic hormone therapy in BRCA mutation carriers. <i>Menopause</i> , 2016 , 23, 1026-7	2.5	20
178	Counselling framework for moderate-penetrance cancer-susceptibility mutations. <i>Nature Reviews Clinical Oncology</i> , 2016 , 13, 581-8	19.4	200
177	Exercise-Induced Dose-Response Alterations in Adiponectin and Leptin Levels Are Dependent on Body Fat Changes in Women at Risk for Breast Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016 , 25, 1195-200	4	21
176	Patient feedback and early outcome data with a novel tiered-binned model for multiplex breast cancer susceptibility testing. <i>Genetics in Medicine</i> , 2016 , 18, 25-33	8.1	44
175	Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy. <i>Gynecologic Oncology</i> , 2016 , 140, 199-203	4.9	188
174	Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. <i>Nature Genetics</i> , 2016 , 48, 374-86	36.3	93
173	Patterns and predictors of BRCA 1/2 testing in young breast cancer survivors.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1514-1514	2.2	1

172	Prospective registry of multiplex testing (PROMPT): A web-based platform to assess cancer risk of genetic variants.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1518-1518	2.2	1
171	Refining Breast Cancer Risk Stratification: Additional Genes, Additional Information. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016 , 36, 44-56	7.1	12
170	Utilizing Remote Real-Time Videoconferencing to Expand Access to Cancer Genetic Services in Community Practices: A Multicenter Feasibility Study. <i>Journal of Medical Internet Research</i> , 2016 , 18, e23	7.6	53
169	Cancer susceptibility mutations in individuals with breast and ovarian cancer using next-generation sequencing.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1515-1515	2.2	0
168	Patient-reported outcomes in a multicenter randomized study of in-person versus telephone disclosure of genetic test results for cancer susceptibility.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1502-1502	2.2	0
167	Identification of genetic test results with conflicting interpretations in prospective registry of multiplex testing (PROMPT).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1510-1510	2.2	0
166	Refining Breast Cancer Risk Stratification: Additional Genes, Additional Information. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016 , 35, 44-56	7.1	15
165	Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. <i>PLoS ONE</i> , 2016 , 11, e0158801	3.7	7
164	Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations. <i>JAMA Oncology</i> , 2016 , 2, 1434-1440	13.4	151
163	Response. <i>Journal of the National Cancer Institute</i> , 2016 , 108,	9.7	2
162	Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. <i>Breast Cancer Research</i> , 2016 , 18, 64	8.3	25
161	Noninvasive Measures of Ventricular-Arterial Coupling and Circumferential Strain Predict Cancer Therapeutics-Related Cardiac Dysfunction. <i>JACC: Cardiovascular Imaging</i> , 2016 , 9, 1131-1141	8.4	59
160	Evaluation of ACMG-Guideline-Based Variant Classification of Cancer Susceptibility and Non-Cancer-Associated Genes in Families Affected by Breast Cancer. <i>American Journal of Human Genetics</i> , 2016 , 98, 801-817	11	86
159	Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. <i>Breast Cancer Research</i> , 2016 , 18, 15	8.3	58
158	Adjuvant ovarian function suppression and cognitive function in women with breast cancer. <i>British Journal of Cancer</i> , 2016 , 114, 956-64	8.7	30
157	An international survey of surveillance schemes for unaffected BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2016 , 157, 319-327	4.4	22
156	Health Care Segregation, Physician Recommendation, and Racial Disparities in BRCA1/2 Testing Among Women With Breast Cancer. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2610-8	2.2	83
155	Baseline Immunoglobulin E Levels as a Marker of Doxorubicin- and Trastuzumab-Associated Cardiac Dysfunction. <i>Circulation Research</i> , 2016 , 119, 1135-1144	15.7	27

154	Population Frequency of Germline BRCA1/2 Mutations. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4183-4185.	2.2	64
153	Genome-wide association studies in women of African ancestry identified 3q26.21 as a novel susceptibility locus for oestrogen receptor negative breast cancer. <i>Human Molecular Genetics</i> , 2016 , 25, 4835-4846	5.6	34
152	Conflicting Interpretation of Genetic Variants and Cancer Risk by Commercial Laboratories as Assessed by the Prospective Registry of Multiplex Testing. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4071-4078	4.7	110
151	A Recurrent ERCC3 Truncating Mutation Confers Moderate Risk for Breast Cancer. <i>Cancer Discovery</i> , 2016 , 6, 1267-1275	24.4	30
150	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. <i>Nature Genetics</i> , 2015 , 47, 164-71	36.3	177
149	Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. <i>JAMA - Journal of the American Medical Association</i> , 2015 , 313, 1347-61	27.4	286
148	Associations between breast density and a panel of single nucleotide polymorphisms linked to breast cancer risk: a cohort study with digital mammography. <i>BMC Cancer</i> , 2015 , 15, 143	4.8	12
147	The use of the Gail model, body mass index and SNPs to predict breast cancer among women with abnormal (BI-RADS 4) mammograms. <i>Breast Cancer Research</i> , 2015 , 17, 1	8.3	52
146	Breast MRI fibroglandular volume and parenchymal enhancement in BRCA1 and BRCA2 mutation carriers before and immediately after risk-reducing salpingo-oophorectomy. <i>American Journal of Roentgenology</i> , 2015 , 204, 669-73	5.4	28
145	Dose-response effects of aerobic exercise on estrogen among women at high risk for breast cancer: a randomized controlled trial. <i>Breast Cancer Research and Treatment</i> , 2015 , 154, 309-18	4.4	29
144	RE: Breast Cancer Risk After Salpingo-Oophorectomy in Healthy BRCA1/2 Mutation Carriers: Revisiting the Evidence for Risk Reduction. <i>Journal of the National Cancer Institute</i> , 2015 , 107,	9.7	23
143	American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3660-7	2.2	360
142	Prevalence of mutations in a panel of breast cancer susceptibility genes in BRCA1/2-negative patients with early-onset breast cancer. <i>Genetics in Medicine</i> , 2015 , 17, 630-8	8.1	101
141	Development of a tiered and binned genetic counseling model for informed consent in the era of multiplex testing for cancer susceptibility. <i>Genetics in Medicine</i> , 2015 , 17, 485-92	8.1	60
140	Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015 , 24, 308-16	4	20
139	Multiplex genetic testing: reconsidering utility and informed consent in the era of next-generation sequencing. <i>Genetics in Medicine</i> , 2015 , 17, 97-8	8.1	36
138	An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. <i>Breast Cancer Research</i> , 2015 , 17, 61	8.3	16
137	Quantitative assessment of background parenchymal enhancement in breast MRI predicts response to risk-reducing salpingo-oophorectomy: preliminary evaluation in a cohort of BRCA1/2 mutation carriers. <i>Breast Cancer Research</i> , 2015 , 17, 67	8.3	41

136	Assessing associations between the AURKA-HMMR-TPX2-TUBG1 functional module and breast cancer risk in BRCA1/2 mutation carriers. <i>PLoS ONE</i> , 2015 , 10, e0120020	3.7	26
135	Gene-panel sequencing and the prediction of breast-cancer risk. <i>New England Journal of Medicine</i> , 2015 , 372, 2243-57	59.2	587
134	DCIS in BRCA1 and BRCA2 mutation carriers: prevalence, phenotype, and expression of oncogenes C-MET and HER3. <i>Journal of Translational Medicine</i> , 2015 , 13, 335	8.5	12
133	CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessment. <i>Clinical Cancer Research</i> , 2015 , 21, 995-1001	12.9	243
132	Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. <i>Journal of Clinical Oncology</i> , 2015 , 33, 244-50	2.2	1171
131	Women In Steady Exercise Research (WISER) Sister: study design and methods. <i>Contemporary Clinical Trials</i> , 2015 , 41, 17-30	2.3	17
130	Characteristics of high risk breast cancer patients with mutations identified by multiplex panel testing.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1511-1511	2.2	1
129	A phase II open-label, multicenter study of single-agent rucaparib in the treatment of patients with relapsed ovarian cancer and a deleterious BRCA mutation.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 5513-5513	2.2	11
128	Interest in and outcomes with return of individual genetic research results for inherited susceptibility to breast cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e12503-e12503	2.2	
127	Information preferences of women with triple-negative breast cancer (TNBC).. <i>Journal of Clinical Oncology</i> , 2015 , 33, e20585-e20585	2.2	
126	Meeting the educational needs of women with triple-negative breast cancer (TNBC).. <i>Journal of Clinical Oncology</i> , 2015 , 33, e20580-e20580	2.2	
125	Uterine cancer (Ut Ca) following risk-reducing salpingo-oophorectomy (RRSO) in women with BRCA mutations (BRCA+): A multicenter, prospective study.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1504-1504	2.2	
124	Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study. <i>European Urology</i> , 2014 , 66, 489-99	10.2	156
123	Modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: systematic review and meta-analysis. <i>Journal of the National Cancer Institute</i> , 2014 , 106, dju091	9.7	134
122	Panel testing for inherited susceptibility to breast, ovarian, and colorectal cancer. <i>Genetics in Medicine</i> , 2014 , 16, 827-9	8.1	9
121	Breast-cancer risk in families with mutations in PALB2. <i>New England Journal of Medicine</i> , 2014 , 371, 497-506	59.6	576
120	Long-term risk of medical conditions associated with breast cancer treatment. <i>Breast Cancer Research and Treatment</i> , 2014 , 145, 233-43	4.4	24
119	Contraceptive use and the role of contraceptive counseling in reproductive-aged women with cancer. <i>Contraception</i> , 2014 , 90, 79-85	2.5	33

118	Impact of shortages of injectable oncology drugs on patient care. <i>American Journal of Health-System Pharmacy</i> , 2014 , 71, 571-8	2.2	30
117	DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers. <i>PLoS Genetics</i> , 2014 , 10, e1004256	6	33
116	Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2014 , 148, 397-406	4.4	42
115	Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research</i> , 2014 , 16, 3416	8.3	46
114	Familial Breast Cancer Risk. <i>Current Breast Cancer Reports</i> , 2013 , 5, 170-182	0.8	6
113	A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity. <i>Cancer Research</i> , 2013 , 73, 265-75	10.1	77
112	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. <i>Nature Genetics</i> , 2013 , 45, 371-84, 384e1-2	36.3	422
111	Incremental impact of breast cancer SNP panel on risk classification in a screening population of white and African American women. <i>Breast Cancer Research and Treatment</i> , 2013 , 138, 889-98	4.4	9
110	A genome-wide association study of breast cancer in women of African ancestry. <i>Human Genetics</i> , 2013 , 132, 39-48	6.3	63
109	Agreement of self-reported hormone receptor status with cancer registry data in young breast cancer patients. <i>Cancer Epidemiology</i> , 2013 , 37, 601-5	2.8	5
108	Fine mapping of breast cancer genome-wide association studies loci in women of African ancestry identifies novel susceptibility markers. <i>Carcinogenesis</i> , 2013 , 34, 1520-8	4.6	24
107	Melanoma genetic testing, counseling, and adherence to skin cancer prevention and detection behaviors. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013 , 22, 607-14	4	28
106	Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer risk. <i>PLoS Genetics</i> , 2013 , 9, e1003173	6	90
105	Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. <i>PLoS Genetics</i> , 2013 , 9, e1003212	6	209
104	Biallelic deleterious BRCA1 mutations in a woman with early-onset ovarian cancer. <i>Cancer Discovery</i> , 2013 , 3, 399-405	24.4	106
103	Are physician recommendations for BRCA1/2 testing in patients with breast cancer appropriate? A population-based study. <i>Cancer</i> , 2013 , 119, 3596-603	6.4	18
102	Risk of metachronous breast cancer after BRCA mutation-associated ovarian cancer. <i>Cancer</i> , 2013 , 119, 1344-8	6.4	37
101	Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. <i>Human Mutation</i> , 2012 , 33, 690-702	4.7	31

100	Lack of association between common single nucleotide polymorphisms in the TERT-CLPTM1L locus and breast cancer in women of African ancestry. <i>Breast Cancer Research and Treatment</i> , 2012 , 132, 341-54	4.4	12
99	Breast and ovarian cancer risk and risk reduction in Jewish BRCA1/2 mutation carriers. <i>Journal of Clinical Oncology</i> , 2012 , 30, 1321-8	2.2	25
98	CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patients. <i>Science Translational Medicine</i> , 2012 , 4, 134ra62	17.5	216
97	Low rates of African American participation in genetic counseling and testing for BRCA1/2 mutations: racial disparities or just a difference?. <i>Journal of Genetic Counseling</i> , 2012 , 21, 676-83	2.5	30
96	Follow-up frequency and compliance in women with probably benign findings on breast magnetic resonance imaging. <i>Academic Radiology</i> , 2012 , 19, 406-11	4.3	16
95	Cancer treatment according to BRCA1 and BRCA2 mutations. <i>Nature Reviews Clinical Oncology</i> , 2012 , 9, 520-8	19.4	56
94	Prophylactic Mastectomy and Risk-Reducing Salpingo-oophorectomy in BRCA1/2 Mutation Carriers. <i>Current Breast Cancer Reports</i> , 2012 , 4, 199-206	0.8	
93	Breast cancer risk and 6q22.33: combined results from Breast Cancer Association Consortium and Consortium of Investigators on Modifiers of BRCA1/2. <i>PLoS ONE</i> , 2012 , 7, e35706	3.7	10
92	Evaluation of 19 susceptibility loci of breast cancer in women of African ancestry. <i>Carcinogenesis</i> , 2012 , 33, 835-40	4.6	59
91	Quality of life in long-term survivors of metastatic breast cancer. <i>Clinical Breast Cancer</i> , 2012 , 12, 119-26	3	20
90	A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012 , 21, 1362-70	4	20
89	Genetic susceptibility to type 2 diabetes and breast cancer risk in women of European and African ancestry. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012 , 21, 552-6	4	10
88	BRCA1 R1699Q variant displaying ambiguous functional abrogation confers intermediate breast and ovarian cancer risk. <i>Journal of Medical Genetics</i> , 2012 , 49, 525-32	5.8	82
87	Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012 , 21, 645-57	4	44
86	Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012 , 21, 134-47	4	411
85	How genetic variant libraries effectively extend gene testing patents: implications for intellectual property and good clinical care. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2943-5	2.2	4
84	Understanding participation by African Americans in cancer genetics research. <i>Journal of the National Medical Association</i> , 2012 , 104, 324-30	2.3	29
83	Modification of BRCA1-Associated Breast and Ovarian Cancer Risk by BRCA1-Interacting Genes. <i>Cancer Research</i> , 2011 , 71, 5792-805	10.1	44

82	Therapeutic approaches for women predisposed to breast cancer. <i>Annual Review of Medicine</i> , 2011 , 62, 295-306	17.4	28
81	The tubal hypothesis of ovarian cancer: caution needed. <i>Lancet Oncology</i> , 2011 , 12, 1089-91	21.7	21
80	Breast Reconstruction [A Historical Perspective on Available Techniques for Patients Electing Bilateral Mastectomy. <i>Current Cancer Therapy Reviews</i> , 2011 , 7, 272-281	0.4	
79	Clinically relevant changes in family history of cancer over time. <i>JAMA - Journal of the American Medical Association</i> , 2011 , 306, 172-8	27.4	33
78	Breast cancer surgery trend changes since the introduction of BRCA1/2 mutation screening: a retrospective cohort analysis of 158 mutation carriers treated at a single institution. <i>Annals of Surgical Oncology</i> , 2011 , 18, 745-51	3.1	8
77	PALB2 mutations in familial breast and pancreatic cancer. <i>Familial Cancer</i> , 2011 , 10, 225-31	3	82
76	Clinical management of hereditary breast cancer syndromes. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2011 , 16, 17-25	2.4	34
75	Risk of ipsilateral breast cancer in BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2011 , 127, 287-96	4.4	66
74	Haplotype structure in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers. <i>Human Genetics</i> , 2011 , 130, 685-99	6.3	15
73	Stumbling blocks on the path to personalized medicine in breast cancer: the case of PARP inhibitors for BRCA1/2-associated cancers. <i>Cancer Discovery</i> , 2011 , 1, 29-34	24.4	39
72	Challenges to the development of new agents for molecularly defined patient subsets: lessons from BRCA1/2-associated breast cancer. <i>Journal of Clinical Oncology</i> , 2011 , 29, 4224-6	2.2	21
71	Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. <i>Human Molecular Genetics</i> , 2011 , 20, 3304-21	5.6	62
70	Common genetic variation at BARD1 is not associated with breast cancer risk in BRCA1 or BRCA2 mutation carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011 , 20, 1032-8	4	13
69	Genetic variation in IGF2 and HTRA1 and breast cancer risk among BRCA1 and BRCA2 carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011 , 20, 1690-702	4	16
68	Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers. <i>Human Molecular Genetics</i> , 2011 , 20, 4732-47	5.6	21
67	Large prospective study of ovarian cancer screening in high-risk women: CA125 cut-point defined by menopausal status. <i>Cancer Prevention Research</i> , 2011 , 4, 1401-8	3.2	42
66	Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. <i>Journal of the National Cancer Institute</i> , 2011 , 103, 105-16	9.7	37
65	Variants at 6q21 implicate PRDM1 in the etiology of therapy-induced second malignancies after HodgkinB lymphoma. <i>Nature Medicine</i> , 2011 , 17, 941-3	50.5	128

64	Long-term reactions to genetic testing for BRCA1 and BRCA2 mutations: does time heal women's concerns?. <i>Journal of Clinical Oncology</i> , 2011 , 29, 4302-6	2.2	55
63	Interplay between BRCA1 and RHMAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer. <i>PLoS Biology</i> , 2011 , 9, e1001199	9.7	73
62	A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. <i>Nature Genetics</i> , 2010 , 42, 885-92	36.3	276
61	Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. <i>Cancer Research</i> , 2010 , 70, 9742-54	10.1	147
60	Common variants associated with breast cancer in genome-wide association studies are modifiers of breast cancer risk in BRCA1 and BRCA2 mutation carriers. <i>Human Molecular Genetics</i> , 2010 , 19, 2886-97	5.6	56
59	Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells. <i>Clinical Cancer Research</i> , 2010 , 16, 3485-94	12.9	212
58	Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. <i>JAMA - Journal of the American Medical Association</i> , 2010 , 304, 967-75	27.4	993
57	Association of the variants CASP8 D302H and CASP10 V410I with breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010 , 19, 2859-68	4	32
56	Common genetic variants and modification of penetrance of BRCA2-associated breast cancer. <i>PLoS Genetics</i> , 2010 , 6, e1001183	6	74
55	Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. <i>Lancet, The</i> , 2010 , 376, 235-44	40	1395
54	Homeostasis of peripheral FoxP3(+) CD4 (+) regulatory T cells in patients with early and late stage breast cancer. <i>Cancer Immunology, Immunotherapy</i> , 2010 , 59, 599-607	7.4	32
53	Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2010 , 124, 195-203	4.4	44
52	Evaluation of established breast cancer risk factors as modifiers of BRCA1 or BRCA2: a multi-center case-only analysis. <i>Breast Cancer Research and Treatment</i> , 2010 , 124, 441-51	4.4	27
51	Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy. <i>Breast Cancer Research and Treatment</i> , 2010 , 121, 389-98	4.4	139
50	Predicting BRCA1 and BRCA2 gene mutation carriers: comparison of PENN II model to previous study. <i>Familial Cancer</i> , 2010 , 9, 495-502	3	39
49	Alcohol consumption and the risk of breast cancer among BRCA1 and BRCA2 mutation carriers. <i>Breast</i> , 2010 , 19, 479-83	3.6	19
48	Preventive surgery is associated with reduced cancer risk and mortality in women with BRCA1 and BRCA2 mutations. <i>LDI Issue Brief</i> , 2010 , 16, 1-4		11
47	Modification of ovarian cancer risk by BRCA1/2-interacting genes in a multicenter cohort of BRCA1/2 mutation carriers. <i>Cancer Research</i> , 2009 , 69, 5801-10	10.1	27

46	Multimodal assessment of protein functional deficiency supports pathogenicity of BRCA1 p.V1688del. <i>Cancer Research</i> , 2009 , 69, 7030-7	10.1	15
45	Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. <i>Journal of the National Cancer Institute</i> , 2009 , 101, 80-7	9.7	650
44	Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. <i>Human Molecular Genetics</i> , 2009 , 18, 4442-56	5.6	91
43	Collapse of the CD27+ B-cell compartment associated with systemic plasmacytosis in patients with advanced melanoma and other cancers. <i>Clinical Cancer Research</i> , 2009 , 15, 4277-87	12.9	38
42	Tamoxifen and the risk of ovarian cancer in BRCA1 mutation carriers. <i>Gynecologic Oncology</i> , 2009 , 115, 135-137	4.9	12
41	No evidence that CDKN1B (p27) polymorphisms modify breast cancer risk in BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2009 , 115, 307-13	4.4	9
40	No evidence that GATA3 rs570613 SNP modifies breast cancer risk. <i>Breast Cancer Research and Treatment</i> , 2009 , 117, 371-9	4.4	10
39	Smoking and the risk of breast cancer in BRCA1 and BRCA2 carriers: an update. <i>Breast Cancer Research and Treatment</i> , 2009 , 114, 127-35	4.4	23
38	Clinical implications of low-penetrance breast cancer susceptibility alleles. <i>Current Oncology Reports</i> , 2009 , 11, 8-14	6.3	4
37	Refining BRCA1 and BRCA2 penetrance estimates in the clinic. <i>Current Breast Cancer Reports</i> , 2009 , 1, 127-130	0.8	1
36	Utilization of religious coping strategies among African American women at increased risk for hereditary breast and ovarian cancer. <i>Family and Community Health</i> , 2009 , 32, 218-27	1.6	4
35	Breast cancer gene variants: separating the harmful from the harmless. <i>Journal of Clinical Investigation</i> , 2009 , 119, 2895-7	15.9	7
34	The relative contribution of point mutations and genomic rearrangements in BRCA1 and BRCA2 in high-risk breast cancer families. <i>Cancer Research</i> , 2008 , 68, 7006-14	10.1	92
33	Factors determining dissemination of results and uptake of genetic testing in families with known BRCA1/2 mutations. <i>Genetic Testing and Molecular Biomarkers</i> , 2008 , 12, 81-91		107
32	Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. <i>Journal of Clinical Oncology</i> , 2008 , 26, 1331-7	2.2	465
31	The clinical management of BRCA1 and BRCA2 mutation carriers. <i>Current Oncology Reports</i> , 2008 , 10, 47-53	6.3	13
30	International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. <i>International Journal of Cancer</i> , 2008 , 122, 2017-22	7.5	268
29	Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. <i>American Journal of Human Genetics</i> , 2008 , 82, 937-48	11	218

28	Large genomic rearrangement in BRCA1 and BRCA2 and clinical characteristics of men with breast cancer in the United States. <i>Clinical Breast Cancer</i> , 2007 , 7, 627-33	3	6
27	Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers. <i>Clinical Breast Cancer</i> , 2007 , 7, 875-82	3	69
26	The prevention of hereditary breast cancer. <i>Seminars in Oncology</i> , 2007 , 34, 401-5	5.5	10
25	Age at first birth and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2007 , 105, 221-8	4.4	38
24	Cancer yield of mammography, MR, and US in high-risk women: prospective multi-institution breast cancer screening study. <i>Radiology</i> , 2007 , 244, 381-8	20.5	299
23	Differential lysis of tumors by polyclonal T cell lines and T cell clones specific for hTERT. <i>Cancer Biology and Therapy</i> , 2007 , 6, 1991-6	4.6	16
22	Telomerase-specific T-cell immunity in breast cancer: effect of vaccination on tumor immunosurveillance. <i>Cancer Research</i> , 2007 , 67, 10546-55	10.1	79
21	Breast cancer risk among male BRCA1 and BRCA2 mutation carriers. <i>Journal of the National Cancer Institute</i> , 2007 , 99, 1811-4	9.7	246
20	Prophylactic oophorectomy in women at increased cancer risk. <i>Current Opinion in Obstetrics and Gynecology</i> , 2007 , 19, 27-30	2.4	47
19	RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. <i>American Journal of Human Genetics</i> , 2007 , 81, 1186-200	11	204
18	Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. <i>Lancet Oncology, The</i> , 2007 , 8, 26-34	21.7	186
17	Cancer risk models: translating family history into clinical management. <i>Annals of Internal Medicine</i> , 2007 , 147, 515-7	8	3
16	Childhood cancer in families with and without BRCA1 or BRCA2 mutations ascertained at a high-risk breast cancer clinic. <i>Cancer Biology and Therapy</i> , 2006 , 5, 1098-102	4.6	23
15	Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. <i>Lancet Oncology, The</i> , 2006 , 7, 223-9	21.7	291
14	Breast cancer screening behaviors among African American women with a strong family history of breast cancer. <i>Preventive Medicine</i> , 2006 , 43, 385-8	4.3	25
13	Low rates of acceptance of BRCA1 and BRCA2 test results among African American women at increased risk for hereditary breast-ovarian cancer. <i>Genetics in Medicine</i> , 2006 , 8, 576-82	8.1	58
12	Satisfaction with genetic counseling for BRCA1 and BRCA2 mutations among African American women. <i>Patient Education and Counseling</i> , 2006 , 63, 196-204	3.1	48
11	Bilateral risk-reducing oophorectomy in BRCA1 and BRCA2 mutation carriers. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2006 , 4, 177-82	7.3	20

10	Knowledge, attitudes, and utilization of BRCA1/2 testing among women with early-onset breast cancer. <i>Genetic Testing and Molecular Biomarkers</i> , 2005 , 9, 48-53		42
9	Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. <i>Journal of Clinical Oncology</i> , 2005 , 23, 7804-10	2.2	339
8	Telomerase vaccination has no detectable effect on SCID-repopulating and colony-forming activities in the bone marrow of cancer patients. <i>Experimental Hematology</i> , 2005 , 33, 1275-80	3.1	37
7	Recruiting African American women to participate in hereditary breast cancer research. <i>Journal of Clinical Oncology</i> , 2005 , 23, 7967-73	2.2	42
6	Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes. <i>Clinical Cancer Research</i> , 2004 , 10, 828-39	12.9	211
5	Application of breast cancer risk prediction models in clinical practice. <i>Journal of Clinical Oncology</i> , 2003 , 21, 593-601	2.2	150
4	Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. <i>Cancer</i> , 2003 , 97, 2972-7	6.4	589
3	Lymphomas of the breast: primary and secondary involvement. <i>Cancer</i> , 2002 , 94, 6-13	6.4	164
2	Recent advances in breast cancer biology. <i>Current Opinion in Oncology</i> , 2002 , 14, 589-93	4.2	10
1	Predictors of skeletal complications in patients with metastatic breast carcinoma. <i>Cancer</i> , 2000 , 89, 363-8.4	8.4	111